2023 international evidence-based guideline pcos glp-1 receptor agonist Highlights from the Guidelines Getting a grip on polycystic

Jones R

Until such evidence is available for retatrutide, therapies with established cardiovascular and renal benefitssuch as semaglutide, supported by SUSTAIN-6 [5] and FLOW [57] trials in people with T2D, and the SELECT trial [58] in people with obesity - should be prioritised in populations with existing cardio-renal disease

Back Chaiborn, C (1 Aug 2011) 'Masters of metabolism: Matthias Tschp and Richard DiMarchi', The Journal of Clinical Investigation , 121/8, 2952

Not "talk to your doctor" repeated seventeen times (though you should do that too, for certain situations)

The downsides (aka side effects) Heres where I get to pop the excitement balloon

Further, it is worth highlighting that survodutide is likely to drive the market in the near future